Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10141MR)

This product GTTS-WQ10141MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10141MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7579MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ3635MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ8405MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ14796MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-70
GTTS-WQ755MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ8487MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ10379MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ58MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2857916
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW